Loading…
Loading…
ARTH (Arch Therapeutics, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
Profitability This table compares Arch Therapeutics and SANUWAVE Health's net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Arch Therapeutics -8,257.70% N/A -730.22% SANUWAVE Health -1.33% -23.83% -20.60% Institutional and Insider Ownership 6.9% of Arch Therapeutics shares are held by institutional investors. Comparatively, 42.5% of SANUWAVE Health
Arch Therapeutics (OTCMKTS:ARTH - Get Free Report) and Biostage (OTCMKTS:BSTG - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk. Volatility and Risk Arch Therapeutics has a beta
SAWC Fall provides a venue to educate clinicians about AC5 Advanced Wound System, present case studies, and continue strategic meetings with wound care companies. SAWC Fall provides a venue to educate clinicians about AC5 Advanced Wound System, present case studies, and continue strategic meetings with wound care companies.
A Study of AC5® Advanced Wound System in Patients with Lower Extremity Wounds to be Featured in a Clinical Poster A Study of AC5® Advanced Wound System in Patients with Lower Extremity Wounds to be Featured in a Clinical Poster
Here is how Arch Therapeutics, Inc. (ARTH) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.
As you may already suspect, there are not a lot of stocks up 1000% year-to-date, but several stocks trading on major exchanges are up 1000% from their lows set earlier in the calendar year. There are also a few fairly-liquid over-the-counter listed stocks that qualify for this category, whether by gaining tenfold since January, or by surging tenfold from an earlier low.
Here is how Arch Therapeutics, Inc. (ARTH) and Haemonetics (HAE) have performed compared to their sector so far this year.
Here is how Arch Therapeutics, Inc. (ARTH) and Cardinal Health (CAH) have performed compared to their sector so far this year.